Last reviewed · How we verify
piperacillin extended infusion
Piperacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Piperacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections including pneumonia, intra-abdominal infections, and urinary tract infections, Pseudomonas aeruginosa infections, Febrile neutropenia in immunocompromised patients.
At a glance
| Generic name | piperacillin extended infusion |
|---|---|
| Sponsor | University Hospital, Ghent |
| Drug class | Beta-lactam antibiotic (ureidopenicillin) |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Piperacillin is an extended-spectrum ureidopenicillin that penetrates bacterial cell walls and irreversibly inhibits transpeptidase enzymes responsible for cross-linking peptidoglycan strands. Extended infusion administration maintains bactericidal concentrations above the minimum inhibitory concentration for a longer duration, improving efficacy against susceptible gram-negative and gram-positive bacteria. This dosing strategy is particularly effective for treating serious infections caused by Pseudomonas aeruginosa and other resistant pathogens.
Approved indications
- Serious bacterial infections including pneumonia, intra-abdominal infections, and urinary tract infections
- Pseudomonas aeruginosa infections
- Febrile neutropenia in immunocompromised patients
Common side effects
- Diarrhea
- Nausea
- Rash
- Phlebitis at infusion site
- Hypersensitivity reactions
- Clostridium difficile-associated diarrhea
Key clinical trials
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients (PHASE4)
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (PHASE4)
- A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia (NA)
- PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock (PHASE3)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study
- Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- piperacillin extended infusion CI brief — competitive landscape report
- piperacillin extended infusion updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI